This account is pending registration confirmation. Please click on the link within the confirmation email previously sent you to complete registration. Need a new registration confirmation email? Click here
EMERYVILLE, Calif., March 12, 2013 (GLOBE NEWSWIRE) -- NovaBay
® Pharmaceuticals, Inc. (NYSE MKT:NBY), a biotechnology company focused on addressing a large unmet therapeutic needs of the global anti-infective market with first-in-class compounds such as its proprietary
Aganocides ®, today announced that Tom Paulson, Chief Financial Officer, will present at the 25th Annual ROTH Conference, held March 17-20, 2013, in Dana Point, California.
Mr. Paulson will be available to respond to questions and to participate in one-on-one meetings with investors attending the conference.
Tuesday, March 19, 2013
5:00 pm PDT
Ritz-Carlton, Laguna Niguel, Dana Point, CA
This presentation will be webcast live at
http://wsw.com/webcast/roth27/nby/ and archived for 90 days in the News & Events section of NovaBay's website at
About NovaBay Pharmaceuticals, Inc.Going Beyond Antibiotics
NovaBay Pharmaceuticals is a biotechnology company focused on addressing the large unmet therapeutic needs of the global anti-infective market with its two distinct categories of compounds, Aganocides® and NeutroPhase® Skin and Wound Cleanser. The Company's four core business units, DermaBay, UroBay, EyeBay and MediBay, are developing treatments that tackle infections in the dermatology, urology, ophthalmology, and wound care areas.
Aganocide ® Compounds
NovaBay's first-in-class Aganocide compounds, led by NVC-422, are patented, topical antimicrobials with a broad spectrum of activity against bacteria, viruses and fungi. Mimicking the mechanism of action that human white blood cells use against infections, Aganocides are not subject to bacterial or fungal resistance, which has been demonstrated in in-vitro and in-vivo studies. Having demonstrated clinical efficacy in Phase 2 proof-of-concept clinical studies, NVC-422 is suited to treat and prevent a wide range of local, non-systemic infections. NovaBay's clinical development activities are focused on three disease areas: